Molecular Composition and Extinction Coefficient of Native Botulinum Neurotoxin Complex Produced by Clostridium botulinum Hall A Strain
- 456 Downloads
Seven distinct strains of Clostridium botulinum (type A to G) each produce a stable complex of botulinum neurotoxin (BoNT) along with neurotoxin-associated proteins (NAPs). Type A botulinum neurotoxin (BoNT/A) is produced with a group of NAPs and is commercially available for the treatment of numerous neuromuscular disorders and cosmetic purposes. Previous studies have indicated that BoNT/A complex composition is specific to the strain, the method of growth and the method of purification; consequently, any variation in composition of NAPs could have significant implications to the effectiveness of BoNT based therapeutics. In this study, a standard analytical technique using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and densitometry analysis was developed to accurately analyze BoNT/A complex from C. botulinum type A Hall strain. Using 3 batches of BoNT/A complex the molar ratio was determined as neurotoxin binding protein (NBP, 124 kDa), heavy chain (HC, 90 kDa), light chain (LC, 53 kDa), NAP-53 (50 kDa), NAP-33 (36 kDa), NAP-22 (24 kDa), NAP-17 (17 kDa) 1:1:1:2:3:2:2. With Bradford, Lowry, bicinchoninic acid (BCA) and spectroscopic protein estimation methods, the extinction coefficient of BoNT/A complex was determined as 1.54 ± 0.26 (mg/mL)−1cm−1. These findings of a reproducible BoNT/A complex composition will aid in understanding the molecular structure and function of BoNT/A and NAPs.
KeywordsBotulinum Clostridium Complex Composition Extinction coefficient Molecular ratio
Botulinum neurotoxin type A
Medium toxin complex
Large toxin complex
Extra-large toxin complex
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Bovine serum albumin
Tris buffered saline containing 0.05 % Tween-20
Botulinum neurotoxin type D
We would like to thank Paul Lindo and Stephen Riding for BoNT/A complex purification. National Institutes of Health Grant 1U01A1078070-02 supported this work.
Conflict of interest
The authors declare that there are no conflicts of interest.
The authors declare that the experiments comply with the current laws of the United States of America.
- 8.East A, Bhandari M, Stacey J, Campbell K, Collins M (1996) Organization and phylogenetic interrelationships of genes encoding components of the botulinum toxin complex in proteolytic Clostridium botulinum types A. Int. J. Syst. Bacteri:1105–1112Google Scholar
- 15.Hauser D, Eklund M, Boquet P, Popoff M (1994) Organization of the botulinum neurotoxin C1 gene and its associated non-toxic protein genes in Clostridium botulinum C. Mol Gen Genet 243:631–640Google Scholar
- 17.Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64(5):1589–1594Google Scholar
- 29.Schantz E, Johnson E (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56(1):80–99Google Scholar
- 30.Sharma S, Singh BR (1998) Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis. J Nat Toxins 7(3):239–253Google Scholar
- 31.Sharma SK, Ramzan MA, Singh BR (2002) Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon 2003:321–331Google Scholar
- 34.Singh BR, Chang T, Kukreja R, Cai S (2013) In: Foster, K The botulinum neurotoxin complex and the role of ancillary proteins. Botulinum neurotoxin-molecular understanding and its applications, springer science neuroscience book series, New York, in press pp 1–47Google Scholar
- 36.Stefanye D, Schantz EJ, Spero L (1967) Amino acid composition of crystalline botulinum toxin, type A. J Bacteriol 94(1):277–278Google Scholar
- 37.Sugii S, Sakaguchi G (1975) Molecular construction of Clostridium botulinum type A toxins. Infect Immun 12(6):1262–1270Google Scholar
- 38.Ting P, Freiman A (2004) The story of Clostridium botulinum- from food poisoning to botox. Clin Med 4(3):258–261Google Scholar